Damora Therapeutics, Inc. (DMRA): Total Liabilities
$20.15M
As of 2025-12-31
$27.58M
As of 2026-06-30
+20.8%
3-year compound annual growth
+27.0%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $20.15M | n/m | 2026-03-19, Balance as of period end |
| 2024-12-31 | $1.30M | -77.9% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $5.90M | -48.4% | 2025-03-19, Balance as of period end |
| 2022-12-31 | $11.44M | +129.1% | 2024-03-08, Balance as of period end |
| 2021-12-31 | $4.99M | -18.3% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $6.11M | -25.0% | 2022-02-17, Balance as of period end |
| 2019-12-31 | $8.14M | n/a | 2021-03-29, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | 2025-12-31 | $20.15M | n/m |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $99.59M | +24.7% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $697.32M | +10.4% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $50.84M | -40.8% |
| Macrogenics Inc (MGNX) | 2025-12-31 | $201.25M | +38.2% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $241.54M | -9.5% |
| Perspective Therapeutics, Inc. (CATX) | 2025-12-31 | $59.94M | +18.9% |
| Savara Inc (SVRA) | 2025-12-31 | $50.30M | +21.4% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $57.16M | -44.6% |
Compare DMRA, NATR, PHAT, ASMB side by side · Screen every company in Pharmaceutical Preparations ↗